Pulse Biosciences Files 8-K
Ticker: PLSE · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Pulse Biosciences filed an 8-K, standard procedure, no immediate news.
AI Summary
Pulse Biosciences, Inc. filed an 8-K on August 26, 2025, reporting other events and financial statements. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California. This filing does not appear to contain specific financial transaction details or material events beyond routine reporting.
Why It Matters
This 8-K filing indicates Pulse Biosciences, Inc. is making a regulatory submission, but it does not disclose specific material events or financial transactions that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information about significant new risks or material adverse events.
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- Electroblate, Inc. (company) — Former company name
- August 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 465696597 (ein) — IRS Employer Identification No.
- 510-906-4600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Pulse Biosciences, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 26, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 26, 2025.
What is the principal executive office address for Pulse Biosciences, Inc.?
The principal executive offices are located at 601 Brickell Key Drive, Suite 1080, Miami, Florida, 33131.
Has Pulse Biosciences, Inc. undergone any name changes?
Yes, the company was formerly known as Pulse Biosciences, Inc. (name change date 20151210) and prior to that, as Electroblate, Inc. (name change date 20141113).
What is the SIC code for Pulse Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Pulse Biosciences, Inc. is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 587 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-08-26 09:03:46
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20250825_8k.htm (8-K) — 25KB
- ex_856819.htm (EX-99.1) — 12KB
- 0001437749-25-027725.txt ( ) — 169KB
- plse-20250826.xsd (EX-101.SCH) — 3KB
- plse-20250826_def.xml (EX-101.DEF) — 11KB
- plse-20250826_lab.xml (EX-101.LAB) — 15KB
- plse-20250826_pre.xml (EX-101.PRE) — 11KB
- plse20250825_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On August 26, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the publication of early data from the Company's clinical study of its CellFX nsPFA Percutaneous Electrode System for the treatment of benign thyroid nodules (the "Study") in the journal Thyroid . The Study was conducted by Professor Stefano Spiezia as a single-arm First-In-Human feasibility study at the Ospedale del Mare center in Naples, Italy. The CellFX nsPFA Percutaneous Electrode System was used under ultrasound guidance to ablate benign thyroid nodules, as either isolated ablations to assess tissue response (Cohorts 1 & 2) or for full treatment of thyroid nodules with therapeutic intent (Cohort 3). Results showed no intranodular fibrosis or scarring on follow-up ultrasounds and fully treated nodules (Cohort 3) had up to 93% reduction in size at 1 year on ultrasound assessment (average 86% reduction), with symptom relief and >48% reduction as early as 2 weeks. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated August 26, 2025 - Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: August 26, 2025 By: /s/ Jon Skinner Jon Skinner Chief Financial Officer (Principal Financial Officer)